UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Clinical cancer research, 2020-02, Vol.26 (4), p.764-774

2020

Volltextzugriff (PDF)

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-10, Vol.36 (30), p.2995-3006

2018

Volltextzugriff (PDF)

ERCC1 and RRM1: Ready for Prime Time?

Journal of clinical oncology, 2013-03, Vol.31 (8), p.1050-1060

2013

Volltextzugriff (PDF)

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Nature reviews. Clinical oncology, 2018-11, Vol.15 (11), p.694-708

2018

Volltextzugriff (PDF)

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

The New England journal of medicine, 2006-09, Vol.355 (10), p.983-991

2006

Volltextzugriff (PDF)

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

Nature reviews. Clinical oncology, 2012-03, Vol.9 (3), p.144-155

2012

Volltextzugriff (PDF)

Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway

PloS one, 2007-12, Vol.2 (12), p.e1337-e1337

2007

Volltextzugriff (PDF)

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Cell cycle (Georgetown, Tex.), 2013-03, Vol.12 (6), p.877-883

2013

Volltextzugriff (PDF)

A novel antibody-based approach to detect the functional ERCC1-202 isoform

DNA repair, 2018-04, Vol.64, p.34-44

2018

Volltextzugriff (PDF)

MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

Clinical cancer research, 2010-02, Vol.16 (4), p.1206-1215

2010

Volltextzugriff (PDF)

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

Cancer research (Chicago, Ill.), 2007-07, Vol.67 (13), p.6253-6262

2007

Volltextzugriff (PDF)

Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer

Cancer discovery, 2023-09, Vol.13 (9), p.1998-2011

2023

Volltextzugriff (PDF)

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2 -Driven Malignancies

Clinical cancer research, 2024-09, p.OF1-OF14

2024

Volltextzugriff (PDF)

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

European journal of cancer (1990), 2020-06, Vol.132, p.211-223

2020

Volltextzugriff (PDF)

ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer

The New England journal of medicine, 2007-10, Vol.357 (15), p.1559-1561

2007

Volltextzugriff (PDF)

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma

ESMO open, 2018-01, Vol.3 (1), p.e000257-e000257, Article e000257

2018

Volltextzugriff (PDF)

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

The Journal of clinical investigation, 2018-04, Vol.128 (4), p.1671-1687

2018

Volltextzugriff (PDF)

Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance

Cell cycle (Georgetown, Tex.), 2016-01, Vol.15 (2), p.295-302

2016

Volltextzugriff (PDF)

Abstract 5006: Docetaxel-platinum-fluorouracil (TPF) induction chemotherapy increases PD-L1 positivity and CD8+ / FOXP3+ immune infiltrates in advanced head and neck squamous cell carcinoma (HNSCC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.5006-5006

2016

Volltextzugriff (PDF)

PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80 (2), p.216-222

2013

Volltextzugriff (PDF)

MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer

Cancer biomarkers : section A of Disease markers, 2016-09, Vol.17 (3), p.323-333

2016

Volltextzugriff (PDF)

19q13- ERCC1 Gene Copy Number Increase in Non–Small-Cell Lung Cancer

Clinical lung cancer, 2013-09, Vol.14 (5), p.549-557

2013

Volltextzugriff (PDF)

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Clinical cancer research, 2020-01, Vol.26 (1), p.242-255

2020

Volltextzugriff (PDF)

Abstract PL05-01: ERCC1 alternative readouts

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.PL05-01-PL05-01

2015

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(83)
Berichte
(1)

Sprache

Englisch
(81)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(44)
Humans
(42)
Oncology
(31)
Lung Neoplasms - Genetics
(22)
Life Sciences
(20)
Lung Neoplasms - Drug Therapy
(20)
Carcinoma, Non-Small-Cell Lung - Genetics
(19)
Female
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(17)
Lung Cancer
(17)
Lung Neoplasms - Pathology
(17)
Male
(17)
Biological And Medical Sciences
(15)
Dna Repair
(15)
Medical Sciences
(15)
Middle Aged
(15)
Carcinoma, Non-Small-Cell Lung - Pathology
(14)
Lung Neoplasms - Metabolism
(13)
Prognosis
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer

ERCC1 and RRM1: Ready for Prime Time?

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

Inhibition of Chk1 kills tetraploid tumor cells through a p53-dependent pathway

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

A novel antibody-based approach to detect the functional ERCC1-202 isoform

MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib

Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2 -Driven Malignancies

Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer

ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade

Translational regulation of the mRNA encoding the ubiquitin peptidase USP1 involved in the DNA damage response as a determinant of Cisplatin resistance

Abstract 5006: Docetaxel-platinum-fluorouracil (TPF) induction chemotherapy increases PD-L1 positivity and CD8+ / FOXP3+ immune infiltrates in advanced head and neck squamous cell carcinoma (HNSCC)

PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy

MMS19 as a potential predictive marker of adjuvant chemotherapy benefit in resected non-small cell lung cancer

19q13- ERCC1 Gene Copy Number Increase in Non–Small-Cell Lung Cancer

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

Abstract PL05-01: ERCC1 alternative readouts

Suchergebnisse filtern